trimetrexate has been researched along with Leukocytopenia in 4 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| " TMTX plasma concentrations were measured after the first dose and the data were fit by two- or three-compartment mammillary pharmacokinetic models." | 1.28 | A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics. ( Donehower, RC; Ettinger, DS; Grochow, LB; Noe, DA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Witte, RS | 1 |
| Yeap, BY | 1 |
| Trump, DL | 1 |
| Pappo, AS | 1 |
| Vats, T | 1 |
| Williams, TE | 1 |
| Bernstein, M | 1 |
| Kamen, BA | 1 |
| Grochow, LB | 1 |
| Noe, DA | 1 |
| Ettinger, DS | 1 |
| Donehower, RC | 1 |
2 trials available for trimetrexate and Leukocytopenia
| Article | Year |
|---|---|
Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial.
Topics: Aged; Anemia; Humans; Leukopenia; Male; Middle Aged; Prostatic Neoplasms; Thrombocytopenia; Treatmen | 1994 |
Phase I trial of trimetrexate in pediatric solid tumors: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Brain Neoplasms; Carcinoma, Renal Cell; Child; Child, Preschool; Female; Follow-U | 1993 |
2 other studies available for trimetrexate and Leukocytopenia
| Article | Year |
|---|---|
Trimetrexate for Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Humans; Leucovorin; Leukopenia; Pneum | 1989 |
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Dose-Response Relationship, Drug; Drug Combinations | 1989 |